{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:01:20Z","timestamp":1794589280219,"version":"4.9.1"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>An 84-year-old man with prostate cancer with neuroendocrine differentiation underwent PET\/CT for staging. <jats:sup>68<\/jats:sup>Ga\u2013prostate-specific membrane antigen PET\/CT did not show significant abnormal tracer accumulation, whereas <jats:sup>18<\/jats:sup>F-OC (<jats:sup>18<\/jats:sup>F-AlF-NOTA-octreotide) PET\/CT showed elevated tracer uptake at multiple sites throughout the body. Therefore, the patient opted to receive 1 cycle of <jats:sup>177<\/jats:sup>Lu-DOTATATE peptide receptor radionuclide therapy with a dose of 200 mCi. Encouragingly, radiographic tumor remission and improvement of clinical symptoms were observed after only 1 cycle of treatment.<\/jats:p>","DOI":"10.1097\/rlu.0000000000004735","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T20:00:35Z","timestamp":1685995235000},"page":"e371-e373","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["177Lu-DOTATATE Therapy in a Case of Castrate-Resistant Prostate Cancer With Neuroendocrine Differentiation"],"prefix":"10.1097","volume":"48","author":[{"given":"Qiaoqiao","family":"Shu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Weifang People's Hospital, Shandong Province, People's Republic of China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,6,6]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/PAS.0000000000000208","article-title":"Proposed morphologic classification of prostate cancer with neuroendocrine differentiation","volume":"38","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/sj.pcan.4500922","article-title":"Clinical implications of neuroendocrine differentiation in prostate cancer","volume":"10","year":"2007","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"bib3-20250621","first-page":"101","article-title":"Prostate cancer with neuroendocrine differentiation\u2014case report","volume":"5","year":"2012","journal-title":"J Med Life"},{"key":"bib4-20250621","first-page":"90","article-title":"Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure","volume":"5","year":"2015","journal-title":"Front Oncol"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/RLU.0000000000002780","article-title":"Excellent response to 177Lu-DOTATATE peptide receptor radionuclide therapy in a patient with progressive metastatic castration-resistant prostate Cancer with neuroendocrine differentiation after 177Lu-PSMA therapy","volume":"44","year":"2019","journal-title":"Clin Nucl Med"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1097\/RLU.0000000000000594","article-title":"Metastatic poorly differentiated prostatic carcinoma with neuroendocrine differentiation: negative on 68Ga-PSMA PET\/CT","volume":"40","year":"2015","journal-title":"Clin Nucl Med"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-DOTATATE for midgut neuroendocrine tumors","volume":"376","year":"2017","journal-title":"N Engl J Med"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/RLU.0000000000001639","article-title":"Clinical response profile of metastatic\/advanced pulmonary neuroendocrine tumors to peptide receptor radionuclide therapy with 177Lu-DOTATATE","volume":"42","year":"2017","journal-title":"Clin Nucl Med"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004735","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T19:06:32Z","timestamp":1750532792000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,6]]},"references-count":8,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004735","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,6]]}}}